Le Lézard
Classified in: Health, Science and technology
Subject: Annual Meeting

The Cannabist Company Holdings Inc. Announces Voting Results of Annual General and Special Meeting of Shareholders


The Cannabist Company Holdings Inc. (NEO: CBST) (OTCQX: CBSTF) (FSE: 3LP) ("The Cannabist Company" or the "Company"), one of the largest and most experienced cultivators, manufacturers and retailers of cannabis products in the U.S., announced today that, at the annual general and special meeting (the "Meeting") of shareholders of the Company ("Shareholders") that was held on Wednesday, November 8, 2023, all nine nominees for the board of directors of the Company were elected, the voting results of which are as follows:

Director

Number and percentage of common
shares(1) of the Company ("Shares")
represented in person or by proxy and
entitled to vote at the Meeting that
were voted FOR

Number and percentage of Shares represented
in person or by proxy and entitled to vote at
the Meeting that were WITHHELD from voting

Nicholas Vita

94,322,352 (99.11%)

845,613 (0.89%)

Michael Abbott

91,777,426 (96.44%)

3,390,539 (3.56%)

Frank Savage

94,451,845 (99.25%)

716,120 (0.75%)

James A.C. Kennedy

93,023,971 (97.75%)

2,143,994 (2.25%)

Jonathan P. May

94,545,768 (99.35%)

622,197 (0.65%)

Jeff Clarke

94,907,502 (99.73%)

260,463 (0.27%)

Alison Worthington

94,909,685 (99.73%)

258,280 (0.27%)

Julie Hill

94,908,061 (99.73%)

259,904 (0.27%)

Rosemary Mazanet

94,910,085 (99.73%)

257,880 (0.27%)

Notes:

(1)   

Assuming conversion of all proportionate voting shares into common shares.

In addition, Shareholders approved the re-appointment of Davidson & Company LLP as auditor of the Company for the ensuing year and the authorization of directors to fix their remuneration. Shareholders also approved amendments to the Company's amended and restated Omnibus Long Term Incentive Plan.

Full details of the foregoing are contained in the Report of Voting Results for the Meeting which will be filed on SEDAR+ at www.sedarplus.ca.

About The Cannabist Company (f/k/a Columbia Care)

The Cannabist Company, formerly known as Columbia Care, is one of the largest and most experienced cultivators, manufacturers and providers of cannabis products and related services, with licenses in 16 U.S. jurisdictions. The Company operates 125 facilities including 94 dispensaries and 31 cultivation and manufacturing facilities, including those under development. Columbia Care, now The Cannabist Company, is one of the original multi-state providers of cannabis in the U.S. and now delivers industry-leading products and services to both the medical and adult-use markets. In 2021, the Company launched Cannabist, its retail brand, creating a national dispensary network that leverages proprietary technology platforms. The company offers products spanning flower, edibles, oils and tablets, and manufactures popular brands including Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber. For more information, please visit www.cannabistcompany.com.


These press releases may also interest you

at 09:20
Inflammasome Therapeutics (https://www.inflam.com), a private company developing a new class of inflammasome inhibitor drugs, Kamuvudines, as therapies for prevalent, degenerative diseases, announced the first patient has been dosed in a...

at 09:17
NanoAi Technologies, a company pioneering advancements in threat detection, today unveiled the NanoAi Technologies analyzer, a groundbreaking device designed to revolutionize security and safety measures across various sectors. This lightweight and...

at 09:15
The "Infectious Diseases Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering. Infectious Diseases Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access...

at 09:05
GE HealthCare today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Portrait VSM vital signs monitor that can provide clinicians with an accurate view of patient vital signs to support...

at 09:05
Merck , known as MSD outside of the United States and Canada, today announced results from STRIDE-10, a Phase 3 trial evaluating V116, the company's investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 34th European...

at 09:00
? 2023 marked by Ceapro's achievement of key milestones and progress toward its next phase of growth ? R&D activities focused on advancement of avenanthramide Phase 1-2a clinical study and the processing of yeast beta glucan along with the...



News published on and distributed by: